敏康口服液论文敏康口服液抗变应性鼻炎的药效学研究.doc

敏康口服液论文：敏康口服液抗变应性鼻炎的药效学研究【中文摘要】探讨敏康口服液抗变应性鼻炎的作用及其初步机制。方法：1变应性鼻炎模型的建立：将OVA、氢氧化铝和百日咳杆菌配制成一定浓度的生理盐水混悬液,分别注入大鼠四个足趾皮下,作为基础致敏,再使用OVA的生理盐水溶液局部激发,最终造成变应性鼻炎大鼠的模型。2敏康口服液抗变应性鼻炎的量效关系研究：以大鼠为实验动物,分组并按上述方法造模后,通过灌胃给以5g/kg、10g/kg、20g/kg、40g/kg和80g/kg五种不同剂量的敏康口服液,持续给药10天后取材测指标。用全自动血液分析仪和荧光分光光度计测量变应性鼻炎大鼠血中嗜酸性粒细胞和组胺的含量,并结合鼻黏膜HE染色形态学观察,确定敏康口服液的抗变应性鼻炎的作用及量效关系。3敏康口服液抗变应性鼻炎的时效关系研究：以大鼠为实验动物,分组并按上述方法造模后,通过灌胃给以敏康口服液,五个不同给药组的持续给药时间分别为3天、5天、7天、10天和14天。各组均在给药结束1h后取材测指标,用全自动血液分析仪和荧光分光光度计测量变应性鼻炎大鼠血中嗜酸性粒细胞和组胺的含量,并结合鼻黏膜HE染色形态学观察,确定敏康口服液抗变应性鼻炎的时效关系。4敏康口服液对RMPC膜稳定性的影响：以大鼠为实验动物,分组并按上述方法造模,提取各组大鼠腹腔肥大细胞,体外给予0.216g/mL、0.432 g/mL和0.864 g/mL三种不同剂量的除菌药液,经孵育1h后,用OVA激发8min,冰浴中止。光镜下观察敏康口服液对肥大细胞膜稳定性的影响。结果：1量效关系研究结果表明：敏康口服液降低变应性鼻炎大鼠血中EOS和HA含量的作用与给药剂量呈现一定的相关性,具有明显的量效关系,EOS和HA含量随着剂量的递增而降低。与空白组相比,模型组大鼠血中EOS和HA含量均显著上升(P0.01),鼻粘膜切片有明显的病理改变；与模型组相比,所有给药组大鼠血中EOS和HA含量均显著下降(P0.01),鼻粘膜切片的病理改变得到了明显改善。2时效关系研究结果表明：敏康口服液降低变应性鼻炎大鼠血中EOS和HA含量的作用与持续给药时间呈现一定的相关性,具有明显的时效关系,EOS和HA含量随着给药时间的延长而降低。与空白组相比,模型组大鼠血中EOS和HA含量均显著上升(P0.01),鼻粘膜切片有明显的病理改变；与模型组相比,所有给药组大鼠血中EOS和HA含量均显著下降(P0.01),鼻粘膜切片的病理改变得到明显改善。3敏康口服液对RMPC膜稳定性影响的研究结果表明：与空白组相比,模型组RMPC形态发生明显变化,阳性细胞比例显著上升(P0.01);与模型组相比,各给药组阳性细胞比例均显著下降(P0.01)。结论：1敏康口服液具有抗变应性鼻炎的作用。2敏康口服液抗变应性鼻炎的作用具有剂量依赖性,最小有效剂量为5g/kg；最大有效剂量为80g/kg。3敏康口服液抗变应性鼻炎的作用具有时间依赖性,起效时间为持续给药3天,作用达到最大药效的持续给药时间为14天。4敏康口服液能明显改善变应性鼻炎鼻黏膜病理状态。5敏康口服液具有明显的稳定肥大细胞膜的作用。【英文摘要】Object:To confirm the effectiveness of Minkang oral solution in treating allergic rhinitis and find out the mechanism underlying.Method:1 Prepare rat model of AR: Mixed OVA, Al(OH)3, and bordetella pertussis together in normal saline. Rats were allergized with this suspension as follows:Injected suspension into the four foot pads on the first day. Five days later they were boosted with injection of physiology saline containing OVA into the rostral parts of the back. And fourteen days later, sensitization was performed every day by dripping OVA in saline into thebilateral nasal cavities.2 Dose-effect relationship of Minkang oral solution: Using rat as model animal, dividing them into different groups and modeling, each of the five medication administration group was intragastrically administrated with Minkang oral solution in different doses (5g/kg, 10g/kg,20g/kg,40g/kg and 80g/kg). The severity of AR was assessed by the content of EOS and HA in peripheral blood by SYSMEX and fluorospectrophotometer, combining the result of pathological section of nasal mucosal.3 Dose-time relationship of Minkang oral solution: Using rat as model animal, dividing them into different groups and modeling, each of the five medication administration group was intragastrically administrated with Minkang oral solution in different duration (3days,5days,7days, 10days and 14days). The severity of AR was assessed by the content of EOS and HA in peripheral blood by SYSMEX and fluorospectrophotometer, combining the result of pathological section of nasal mucosal.4 Influence in the stabilization of membrane of RMPC: Using rat as model animal, and extracting RMPC after immunized, cells of medication administration groups were cultured in buffer A, containing different concentration of aseptic Minkang oral solution (0.216g/mL,0.432 g/mL, and 0.864g/mL). The result was observed via inverted microscope.Result:1 Dose-effect relationship of Minkang oral solution: The dose-effect relationship was confirmed by assessing the content of EOS and HA in peripheral blood. In the dose rank of this experiment, the content of EOS and HA decreased according to the increasing of dosage. Comparing to the blank control group,content of EOS and HA were obviously higher in model group (P0.01),and section of nasal mucosal revealed sever pathological changes;on the contrast, content of EOS and HA were all obviously decreased in medication administration groups contrasting with model group(P0.01),and pathological changes of nasal mucosal were ameliorated.2 Dose-time relationship of Minkang oral solution: The dose-time relationship was confirmed by assessing the content of EOS and HA in peripheral blood.In the dose rank of this experiment,the content of EOS and HA decreased according to the increasing of dosage.Comparing to the blank control group, content of EOS and HA were obviously higher in model group (P0.01),and section of nasal mucosal revealed sever pathological changes;on the contrast, content of EOS and HA were all obviously decreased in medication administration groups contrasting with model group(P0.01),and pathological changes of nasal mucosal were ameliorated.3 Influence in the stabilization of membrane of RMPC: The rate of positive cell in model group was obviously higher than that in blank control group (P0.01),and the rate in medication administration groups were obviously lower than that in model group(P0.01).Conclusion:1 Minkang oral solution is effective in treating allergic rhinitis. 2 The minimal effective dose of Minkang oral solution in healing allergic rhinitis is 5g/kg;and the maximal effective dose is 80g/kg.3 Minkang oral solution began to take effect in 3 days,and it would approach the maximal effect in 14 days.4 Minkang oral solution is able to ameliorate pathology changes in nasal mucosal.5 Minkang oral solution is able to stabilize the membrane of RMPC.【关键词】敏康口服液 抗变应性鼻炎 药效学 机制【英文关键词】Minkang oral solution anti-allergic rhinitis pharmacodynamics mechanism【目录】敏康口服液抗变应性鼻炎的药效学研究缩略语表4-6摘要6-8ABSTRACT8-10前言11-12文献综述12-25一 传统医学对变应性鼻炎的认识12-141 “鼻鼽”概念的产生和发展122 鼻鼽的病因病机和传统治疗方法12-14二 现代医学对变应性鼻炎的认识14-201 变应性鼻炎的病因和机制